Unusual Volume At Biotech Stocks: Aastrom Biosciences (NASDAQ:ASTM), 22nd Century Group (NYSEMKT:XXII), Dyax Corp. (NASDAQ:DYAX), Exelixis (NASDAQ:EXEL)



Over the past few trading days, sleepy microcap Aastrom Biosciences Inc (NASDAQ:ASTM) has exploded from $3.88 3/19/14 to a peak of $6.24 after a positive article from respected analyst Jason Napodano. Seeking Alpha’s sophisticated readership is more than capable of analyzing Aastrom Biosciences Inc (NASDAQ:ASTM)’s balance sheet. Aastrom Biosciences Inc (NASDAQ:ASTM) stock performance was -15.21% in last session and finished the day at $4.18. Traded volume was 1.06million shares in the last session and the average volume of the stock remained 329.73K shares. The beta of the stock remained 0.85. Aastrom Biosciences Inc (NASDAQ:ASTM) insider ownership is 3.27%.

Share of 22nd Century Group Inc (NYSEMKT:XXII) shares yesterday traded down, when a stock takes a downturn it scares many investors, but 22nd Century Group Inc (NYSEMKT:XXII) is a different case, the fall in the stock price is seen by analysts as a perfect opportunity to buy as things are poised to get better from here. 22nd Century Group Inc (NYSEMKT:XXII) dropped
-1.86 percent to $3.16 Wednesday on volume of 3.43million shares. The intra-day range of the stock was $3.10 to $4.00. 22nd Century Group Inc (NYSEMKT:XXII) has a market capitalization of $184.08million.

RBC Capital started coverage on shares of Dyax Corp. (NASDAQ:DYAX) in a research report released on Tuesday morning, TheFlyOnTheWall.com reports. The firm issued an outperform rating and a $15.00 price objective on the stock. Dyax Corp. (NASDAQ:DYAX)’s stock on Mar 26, 2014 reported a decrease of -7.38% to the closing price of $8.28. Its fifty two weeks range is $2.26 -$10.99. The total market capitalization recorded $1.11billion. The overall volume in the last trading session was 4.96million shares. In its share capital, DYAX has 119.57million outstanding shares.

Exelixis, Inc. (NASDAQ:EXEL) announced that the Independent Data Monitoring Committee (IDMC) notified the company today that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis Inc. (NASDAQ:EXEL) continues to anticipate top-line data from COMET-1 in 2014. On Wednesday, shares of Exelixis, Inc. (NASDAQ:EXEL) dropped -39.36% to close the day at $3.90. Company return on investment (ROI) is -48.50% and its monthly performance is recorded as -44.53%. Exelixis, Inc. (NASDAQ:EXEL) quarterly revenue growth is -34.59%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone